The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic value of HER2 on breast cancer survival.
Nora Katzorke
No relevant relationships to disclose
Brigitte Kathrin Rack
Honoraria - Novartis; Veridex
Lothar Haeberle
No relevant relationships to disclose
Julia Katharina Neugebauer
No relevant relationships to disclose
Carola Anna Melcher
No relevant relationships to disclose
Carsten Hagenbeck
No relevant relationships to disclose
Helmut Forstbauer
No relevant relationships to disclose
Hans Ulrich Ulmer
No relevant relationships to disclose
Ulrike Soeling
No relevant relationships to disclose
Rolf Kreienberg
No relevant relationships to disclose
Tanja N. Fehm
Honoraria - Novartis
Andreas Schneeweiss
No relevant relationships to disclose
Matthias W. Beckmann
No relevant relationships to disclose
Peter A. Fasching
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Amgen; Novartis
Wolfgang Janni
Honoraria - Novartis; Roche; Veridex
Research Funding - Novartis